A Phase I, Randomised, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Ascending, Single, Intravenous Doses of MOTREM (LR12) in Healthy Male Subjects

Trial Profile

A Phase I, Randomised, Placebo Controlled Study to Assess the Safety, Tolerability and Pharmacokinetic Profiles of Ascending, Single, Intravenous Doses of MOTREM (LR12) in Healthy Male Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Mar 2018

At a glance

  • Drugs Nangibotide (Primary)
  • Indications Myocardial infarction; Septic shock
  • Focus Adverse reactions; First in man
  • Sponsors Inotrem
  • Most Recent Events

    • 15 Nov 2017 According to an Inotrem media release, based on the data of this trial, European Medicines Agency (EMA) has granted access to its PRIority MEdicines (PRIME) scheme for MOTREMTM in the field of septic shock.
    • 26 Sep 2016 New trial record
    • 13 Sep 2016 Results published in the Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top